Peptide stability table: difference between revisions
Diff·revision 8 → 9·16:04, 15 Feb 2025
Difference between revision 8 and revision 9 of Peptide stability table. 8 lines changed; the page grew by 1,517 bytes.
| Revision 8 — 22:21, 4 Feb 2025 ConsensusConal (talk) expand the table so the third syringe scale is covered 2,084 bytes +145 | Revision 9 — 16:04, 15 Feb 2025 CiteBot (talk) bot: normalise unit spacing 3,601 bytes +1,517 | ||
|---|---|---|---|
| 20 | Filter by compound name, or by storage class. Sorting is available on every column. | 20 | Filter by compound name, or by storage class. Sorting is available on every column. |
| 21 | 21 | ||
| + | 22 | == How to read the columns == | |
| + | 23 | ; Lyophilised : Conditions and interval reported for the dry solid in its sealed container. A lyophilised peptide is far more stable than the same peptide in solution, because the degradation pathways that matter — [[Deamidation|deamidation]], [[Methionine oxidation|oxidation]] and [[Peptide aggregation|aggregation]] — all require water or mobility.{{r|manning}} | |
| + | 24 | ; Reconstituted : Conditions and interval after dissolution. This is the column with the weakest sourcing across the table, and the one carrying the maintenance banner: for approved products it comes from labelling, and for research compounds it is usually an extrapolation. | |
| + | 25 | ; Diluent : What the figure applies to. [[Bacteriostatic water|Bacteriostatic water]] and [[Sterile water for injection|unpreserved water]] are not interchangeable for the purpose of a storage interval, because the interval for a multi-puncture container depends on the preservative. | |
| + | 26 | ; Light : Whether photodegradation is reported as significant. Tryptophan- and tyrosine-containing sequences are the usual concern. | |
| + | 27 | ; Basis : Whether the row rests on manufacturer labelling, a published stability study, or an extrapolation. Rows marked ''extrapolated'' should not be cited as evidence about the compound named. | |
| + | 28 | ||
| 22 | == References == | 29 | == References == |
| 23 | {{reflist}} | 30 | {{reflist}} |
| 24 | <ref name="ich">International Council for Harmonisation, ''Q1A(R2): Stability Testing of New Drug Substances and Products'' (2003).</ref> | 31 | <ref name="ich">International Council for Harmonisation, ''Q1A(R2): Stability Testing of New Drug Substances and Products'' (2003).</ref> |
| + | 32 | <ref name="manning">Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. "Stability of protein pharmaceuticals: an update." ''Pharmaceutical Research'' 27(4):544–575 (2010). DOI:10.1007/s11095-009-0045-6. PMID 20143256.</ref> | |
| 25 | 33 | ||
| 26 | {{DEFAULTSORT:Peptide stability table}} | 34 | {{DEFAULTSORT:Peptide stability table}} |